Eduardo Rodríguez Bocanegra

Mr. Eduardo Rodríguez Bocanegra

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
ELElisabeth M. van Leeuwen
Elisabeth M. van Leeuwen
EEEszter Emri
Eszter Emri
BMBénédicte MJ Merle
Bénédicte MJ Merle
JCJohanna M. Colijn
Johanna M. Colijn
EKEveline Kersten
Eveline Kersten
Imre LengyelImre Lengyel
Imre Lengyel
There is an urgency to find new treatment strategies that could prevent or delay the onset or progression of AMD. Different classes of lipids and lipoproteins metabolism genes have been associated with AMD in a multiple ways, but despite the ever-increasing knowledge base, we still do not understand fully how circulating lipids or local lipid metabolism contribute to AMD. It is essential to clarify whether dietary lipids, systemic or local lipoprotein metabolismtrafficking of lipids in the retina should be targeted in the disease. In this article, we critically evaluate what has been reported in the literature and identify new directions needed to bring about a significant advance in our understanding of the role for lipids in AMD. This may help to develop potential new treatment strategies through targeting the lipid homeostasis.

1 November 2012 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
SBS. Bocanegra-Pérez
S. Bocanegra-Pérez
MVM. Vicente-Barrero
M. Vicente-Barrero
MKM. Knezevic
M. Knezevic
JCJ.M. Castellano-Navarro
J.M. Castellano-Navarro
EBEduardo Rodríguez Bocanegra
Eduardo Rodríguez Bocanegra
ARA. Ramos-Macías
A. Ramos-Macías

31 December 2019 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
LVLourdes Valdés-Sánchez
Lourdes Valdés-Sánchez
SCSofia M. Calado
Sofia M. Calado
BCBerta de la Cerda
Berta de la Cerda
AAAna Aramburu
Ana Aramburu
AGAna Belén García-Delgado
Ana Belén García-Delgado
Francisco J. Diaz CorralesFrancisco J. Diaz Corrales
Francisco J. Diaz Corrales
Background: Mutations in pre-mRNA splicing factorPRPF31can lead to retinitis pigmentosa (RP). Although the exact disease mechanism remains unknown, it has been hypothesized that haploinsufficiency might be involved in the pathophysiology of the disease.Methods: In this study, we have analyzed a mouse model containing the p.A216P mutation inPrpf31gene.Results: We found that mutant Prpf31 protein produces cytoplasmic aggregates in the retinal pigment epithelium and decreasing the protein levels of this splicing factor in the nucleus. Additionally, normal protein was recruited in insoluble aggregates when the mutant protein was overexpressed in vitro. In response to protein aggregation,Hspa4lis overexpressed. This member of the HSP70 family of chaperones might contribute to the correct folding and solubilization of the mutant protein, allowing its translocation to the nucleus.Conclusions: Our data suggests that a mechanism haploinsufficiency and dominant-negative is involved in retinal degeneration due to mutations inPRPF31.HSP70 over-expression might be a new therapeutic target for the treatment of retinal degeneration due toPRPF31mutations.

Verified
Journal Article
Open access
PDF file
ADAnna Duarri
Anna Duarri
EBEduardo Rodríguez Bocanegra
Eduardo Rodríguez Bocanegra
GNGema Martínez Navarrete
Gema Martínez Navarrete
MBMarc Biarnés
Marc Biarnés
MGMiriam García
Miriam García
JMJordi Monés
Jordi Monés
Background: The aim of this study was to test the feasibility and safety of subretinal transplantation of human induced pluripotent stem cell (hiPSC)-derived retinal pigment epithelium (RPE) cells into the healthy margins and within areas of degenerative retina in a swine model of geographic atrophy (GA). Methods: Well-delimited selective outer retinal damage was induced by subretinal injection of NaIO3 into one eye in minipigs (n = 10). Thirty days later, a suspension of hiPSC-derived RPE cells expressing green fluorescent protein was injected into the subretinal space, into the healthy margins, and within areas of degenerative retina. In vivo follow-up was performed by multimodal imaging. Post-mortem retinas were analyzed by immunohistochemistry and histology. Results: In vitro differentiated hiPSC-RPE cells showed a typical epithelial morphology, expressed RPE-related genes, and had phagocytic ability. Engrafted hiPSC-RPE cells were detected in 60% of the eyes, forming mature epithelium in healthy retina extending towards the border of the atrophy. Histological analysis revealed RPE interaction with host photoreceptors in the healthy retina. Engrafted cells in the atrophic zone were found in a patchy distribution but failed to form an epithelial-like layer. Conclusions: These results might support the use of hiPSC-RPE cells to treat atrophic GA by providing a housekeeping function to aid the overwhelmed remnant RPE, which might improve its survival and therefore slow down the progression of GA.

1 January 2012 in Medicina Oral Patología Oral y Cirugia Bucal
Verified
Journal Article
Open access
BPBocanegra- Perez
Bocanegra- Perez
MVM. Vicente-Barrero
M. Vicente-Barrero
MSManuel Sosa-Henríquez
Manuel Sosa-Henríquez
EBEduardo Rodríguez Bocanegra
Eduardo Rodríguez Bocanegra
JLJm. Liminana-Canal
Jm. Liminana-Canal
ARA. Ramos-Macias
A. Ramos-Macias
Osteonecrosis of the jaws is a clinical entity described and linked to treatment with bisphosphonates in 2003. Its real incidence is unknown and it could increase due to the large number of patients treated with these drugs, and its cumulative effect on the bone. State of the art knowledge regarding its etiopathogeny, clinical course and suitable treatments is limited. To study the clinical characteristics of 44 patients with bisphosphonate-related osteonecrosis of the jaws and the state of their bone mineral metabolism: bone remodeling state, prevalence of fractures, bone mineral density study, and assessment of the different treatment strategies. Observational. Information was gathered prospectively through interviews, clinical examinations, additional tests and review of medical records. We studied 16 men and 28 women with a mean age of 64.7 years. Breast cancer was the most frequent underlying disease. Zoledronate was used in 82% of the cases and in the non-oncology group of patients; alendronate was the most frequently used bisphosphonate. The mean duration of the zoledronate and alendronate treatments was 25 months and 88 months respectively. The lower jaw was the most frequent location, and previous exodontias-among the triggering factors known-were the most closely linked to its onset. We found considerable osteoblastic activity in patients suffering from neoplasia, with artifacts present in their bone densitometry and a high percentage of vertebral fractures. According to our results, osteonecrosis of the jaws affects elderly patients. We found a direct relationship between the duration of exposure and the accumulated dose. Other relevant factors are: Poor oral and dental health, corticoids, diabetes and teeth extractions. In essence, it is a clinical diagnosis. Prevention is the best strategy to handle this clinical entity.

4 July 2018 in Expert Review of Precision Medicine and Drug Development
Verified
Journal Article
Closed access
MBMarc Biarnés
Marc Biarnés
VVVassil Vassiliev
Vassil Vassiliev
ENEverson Nogoceke
Everson Nogoceke
EEEszter Emri
Eszter Emri
EBEduardo Rodríguez Bocanegra
Eduardo Rodríguez Bocanegra
Tunde PetoTunde Peto
Tunde Peto
Introduction: With the aging population, diseases such as age-related macular degeneration (AMD) will become more prevalent. This will increase the demand for provision of care on affected individuals, society, and the health-care system. To develop the best, individually tailored treatment for every patient, however, remains challenging. Areas covered: Recent identifications of interactions between environmental, lifestyle, genetic, and non-genetic factors opened the potential for developing personalized approaches for the prevention and treatment of AMD. In this review, we will discuss the implications of these interactions for early to late disease stage conversion, for neovascularization, and for cell atrophy. We will put the findings of recent studies within the context of the regulatory framework requirements surrounding the development of personalized medicine approach to AMD. Expert commentary: Precision medicine is now at a stage that it has its theoretical framework in place for the management of risk for patients with AMD requiring early diagnosis and timely treatment as several key components for such an approach are now clearly identified and are being applied to clinical developments successfully.